MAb 4C5 is a cell impermeable, anti-HSP90 murine monoclonal antibody, originally produced using hybridoma technology. We have previously shown that mAb 4C5 specifically recognizes both the α- and to a lesser extent the β-isoform of HSP90. Additionally, in vitro and in vivo studies revealed that by selectively inhibiting the function of cell-surface HSP90, mAb 4C5 significantly impairs cancer cell invasion and metastasis. Here we describe the reconstitution of mAb 4C5 into a mouse-human chimera. More importantly we report that mAb 4C5 and consequently its chimeric counterpart are completely devoid of heavy chain and consist only of a functional kappa light chain dimer. The chimeric antibody is shown to retain the original antibody's specificity and functional properties. Thus it is capable of inhibiting the function of surface HSP90, leading to reduced cancer cell invasion in vitro. Finally, we present in vivo evidence showing that the chimeric 4C5 significantly inhibits the metastatic deposit formation of MDA-MB-453 cells into the lungs of SCID mice. These data suggest that a chimeric kappa light chain antibody could be potentially used as an anti-cancer agent, thereby introducing a novel type of antibody fragment, with reduced possible adverse immunogenic effects, into cancer therapeutics.
References
[1]
Bagatell R, Whitesell L (2004) Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 3: 1021–1030.
[2]
Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR (2006) Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 31: 164–172.
[3]
Neckers L (2002) Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8: S55–61.
[4]
Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5: 761–772.
[5]
Cheng CF, Guan S, Fedesco M, Fan J, Li Y, et al. (2008) TGF{alpha}-Stimulated Secretion of HSP90{alpha}: Using LRP-1/CD91 Receptor To Promote Human Skin Cell Migration Against TGF{beta}-Rich Environment In Wound Healing. Mol Cell Biol.
[6]
Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, et al. (2004) Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 6: 507–514.
[7]
Li W, Li Y, Guan S, Fan J, Cheng CF, et al. (2007) Extracellular heat shock protein-90alpha: linking hypoxia to skin cell motility and wound healing. Embo J 26: 1221–1233.
[8]
Sidera K, Samiotaki M, Yfanti E, Panayotou G, Patsavoudi E (2004) Involvement of cell surface HSP90 in cell migration reveals a novel role in the developing nervous system. J Biol Chem 279: 45379–45388.
[9]
Sidera K, Patsavoudi E (2008) Extracellular HSP90: conquering the cell surface. Cell Cycle 7: 1564–1568.
[10]
Tsutsumi S, Neckers L (2007) Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci 98: 1536–1539.
[11]
Stellas D, Karameris A, Patsavoudi E (2007) Monoclonal antibody 4C5 immunostains human melanomas and inhibits melanoma cell invasion and metastasis. Clin Cancer Res 13: 1831–1838.
[12]
McCready J, Sims JD, Chan D, Jay DG (2010) Secretion of extracellular hsp90alpha via exosomes increases cancer cell motility: a role for plasminogen activation. BMC Cancer 10: 294.
[13]
Song X, Wang X, Zhuo W, Shi H, Feng D, et al. (2010) The regulatory mechanism of extracellular Hsp90{alpha} on matrix metalloproteinase-2 processing and tumor angiogenesis. J Biol Chem 285: 40039–40049.
[14]
Stellas D, El Hamidieh A, Patsavoudi E (2010) Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell Biol 11: 51.
[15]
Tsutsumi S, Scroggins B, Koga F, Lee MJ, Trepel J, et al. (2008) A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene 27: 2478–2487.
[16]
Wang X, Song X, Zhuo W, Fu Y, Shi H, et al. (2009) The regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancy. Proc Natl Acad Sci U S A 106: 21288–21293.
[17]
Thomaidou D, Patsavoudi E (1993) Identification of a novel neuron-specific surface antigen in the developing nervous system, by monoclonal antibody 4C5. Neuroscience 53: 813–827.
[18]
Thomaidou D, Dori I, Patsavoudi E (1995) Developmental expression and functional characterization of the 4C5 antigen in the postnatal cerebellar cortex. J Neurochem 64: 1937–1944.
[19]
Yfanti E, Nagata I, Patsavoudi E (1998) Migration behavior of rodent granule neurons in the presence of antibody to the 4C5 antigen. J Neurochem 71: 1381–1389.
[20]
Yfanti E, Sidera K, Margaritis LH, Patsavoudi E (2004) The 4C5 antigen is associated with Schwann cell migration during development and regeneration of the rat peripheral nervous system. Glia 45: 39–53.
[21]
Sidera K, Gaitanou M, Stellas D, Matsas R, Patsavoudi E (2008) A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. J Biol Chem 283: 2031–2041.
[22]
Boulianne GL, Hozumi N, Shulman MJ (1984) Production of functional chimaeric mouse/human antibody. Nature 312: 643–646.
[23]
Morrison SL, Wims LA, Oi VT (1988) Genetically engineered antibody molecules: new tools for cancer therapy. Cancer Invest 6: 185–192.
[24]
Sahagan BG, Dorai H, Saltzgaber-Muller J, Toneguzzo F, Guindon CA, et al. (1986) A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen. J Immunol 137: 1066–1074.
[25]
Barbas CF 3rd, Burton DR (1994) Monoclonal antibodies from combinatorial libraries.
[26]
Kabat EA, Wu TT (1991) Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites. J Immunol 147: 1709–1719.
[27]
Sastry L, Alting-Mees M, Huse WD, Short JM, Sorge JA, et al. (1989) Cloning of the immunological repertoire in Escherichia coli for generation of monoclonal catalytic antibodies: construction of a heavy chain variable region-specific cDNA library. Proc Natl Acad Sci U S A 86: 5728–5732.
[28]
Novotny J, Bruccoleri RE, Saul FA (1989) On the attribution of binding energy in antigen-antibody complexes McPC 603, D1.3, and HyHEL-5. Biochemistry 28: 4735–4749.
[29]
Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G (1989) Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341: 544–546.
Muyldermans S, Cambillau C, Wyns L (2001) Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains. Trends Biochem Sci 26: 230–235.
[32]
Winter G, Milstein C (1991) Man-made antibodies. Nature 349: 293–299.
[33]
Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT (2003) Serum test for assessment of patients with Bence Jones myeloma. Lancet 361: 489–491.
[34]
Stevens FJ, Solomon A, Schiffer M (1991) Bence Jones proteins: a powerful tool for the fundamental study of protein chemistry and pathophysiology. Biochemistry 30: 6803–6805.
Sun M, Li L, Gao QS, Paul S (1994) Antigen recognition by an antibody light chain. J Biol Chem 269: 734–738.
[37]
Nishimura E, Mochizuki K, Kato M, Hashizume S, Haruta H, et al. (1999) Recombinant light chain of human monoclonal antibody HB4C5 as a potentially useful lung cancer-targeting vehicle. Hum Antibodies 9: 111–124.
[38]
Masat L, Wabl M, Johnson JP (1994) A simpler sort of antibody. Proc Natl Acad Sci U S A 91: 893–896.
[39]
Pereira B, Benedict CR, Le A, Shapiro SS, Thiagarajan P (1998) Cardiolipin binding a light chain from lupus-prone mice. Biochemistry 37: 1430–1437.
[40]
Dubnovitsky AP, Kravchuk ZI, Chumanevich AA, Cozzi A, Arosio P, et al. (2000) Expression, refolding, and ferritin-binding activity of the isolated VL-domain of monoclonal antibody F11. Biochemistry (Mosc) 65: 1011–1018.
[41]
Gaitanou M, Buanne P, Pappa C, Georgopoulou N, Mamalaki A, et al. (2001) Cloning, expression and localization of human BM88 shows that it maps to chromosome 11p15.5, a region implicated in Beckwith-Wiedemann syndrome and tumorigenesis. Biochem J 355: 715–724.
[42]
Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning. A laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
[43]
Charlton KA (2004) Expression and isolation of recombinant antibody fragments in E. coli. Methods Mol Biol 248: 245–254.
[44]
Patsavoudi E, Hurel C, Matsas R (1991) Purification and characterization of neuron-specific surface antigen defined by monoclonal antibody BM88. J Neurochem 56: 782–788.
[45]
Heimburg J, Yan J, Morey S, Glinskii OV, Huxley VH, et al. (2006) Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11. Neoplasia 8: 939–948.
